In 2016, the integration frequency and clinical relevance of the HBV virus in liver cancer were studied, confirming that the Chr5p15.33 (TERT-CLPTM1L) region is the hottest spot of HBV integration (the integration frequency in tumor samples was approximately 25%), and that integration events in this region could lead to poor prognosis [19]. This evidence concerns the gene TERT and liver cancer.